J

Johnson & Johnson

Makes prescription drugs and medical devices

Technical Product Manager - Intercompany & Value Chain Management

Full-TimePosted on 10/19/2026Deadline 10/27/26
No salary listed
Expert
Bachelor's
Hyderabad, Telangana, India+1 moreMore locations: Bengaluru, Karnataka, India
HybridHybrid work; the position summary identifies Bangalore as the role location, while ATS also lists Hyderabad.
ProductTechnical Product Management

About the job

Requirements
  • A bachelor's degree in management accounting, finance, or supply chain is required.
  • At least 3 years of progressive experience in program or people-management leadership roles within Operations, Supply Chain, or large transformation programs is required.
  • At least 10 years of Supply Chain Technology experience is required.
  • At least 3 years of ERP platform experience in the healthcare or health services industry is required.
  • Deep end-to-end understanding of financial and logistical flows in multinational operations and how Plan, Make, Deliver, Finance, and Tax functions integrate.
  • Strong knowledge of SAP ERP integration across Production Planning, Materials Management, Sales & Distribution, and Financial Accounting, as well as system integration with the ERP ecosystem.
  • Understanding of end-to-end business process linkages across Plan, Source, Make, Deliver, Finance, and Master Data.
  • Experience in the pharmaceutical or healthcare industry and knowledge of SOX and GxP compliance regulations.
  • Experience with Agile methodology and strong understanding of the Software Development Lifecycle Management model and documentation.
  • Demonstrated leadership skills and success leading multifunctional, self-organized teams.
  • Experience working in a global environment and leading teams across multiple countries.
  • Experience effectively collaborating with and managing partners.
  • Strong analytical and problem-solving skills, including the ability to assess situations accurately and make well-informed decisions.
Responsibilities
  • Own the vision and prioritization of new technical features and enhancements for Intercompany and Value Chain Management capabilities to meet business needs.
  • Establish technology roadmaps to deliver business and customer value efficiently and effectively for Intercompany requirements.
  • Balance business value with technical feasibility when prioritizing features, optimizing cost, and improving delivery efficiency.
  • Refine the backlog by adding necessary technical features and epics; work with suppliers and Product Owners to ensure supplier-delivered capacity and architectural integration are understood.
  • Help Product Owners prioritize their backlogs, manage product and platform constraints, resolve cross-team dependencies, and manage demand intake as required.
  • Own solution design and implementation of Intercompany and Value Chain Management capabilities for Innovative Medicine on the ERP platform and their integration with the ERP ecosystem.
  • Drive business-process standardization and strategies for best-in-class ERP Intercompany flows and Value Chain Management design.
  • Apply understanding of BTP capabilities and integration mechanisms to automate end-to-end transactions.
  • Engage with business and functional teams to provide suitable technical solutions aligned with Transcend program design and implementation standards.
  • Drive selection of product and platform solution options; work with Engineering to assess technical elements before user testing and balance technical debt.
  • Provide technical leadership in designing and architecting ERP solutions for best-in-class integrations across end-to-end Intercompany flows, including integration technologies.
  • Deliver technical outcomes and realize value in partnership with the business workstream lead.
  • Manage the integrated build with Engineering to ensure the end-to-end build of a solution component is compliant and works as designed.
  • Oversee Engineering's technical testing planning and execution, and support the business workstream lead in planning and executing User Acceptance Testing.
  • Apply compliance requirements within the scope of responsibility and ensure SDLC documentation, system configuration, and compliance activities are up to date.
  • Measure capabilities continually against demand volume, complexity, business challenges, and improvement needs within value streams.
  • Act as JJT workstream lead for Intercompany and Value Chain Management integration topics, partnering with business stakeholders.
  • Lead an international cross-regional team of Product Analysts through project design, execution, and deployment.
  • Coordinate, lead, coach, motivate, and inspire the team to deliver agreed plans and continuously improve.
  • Help shape and grow the JJT organization to enable a global intake, build, and sustain process for parallel program releases and ongoing operations, projects, and enhancements as Transcend goes live.
  • Foster continuous improvement and innovation.
Desired Qualifications
  • Applied knowledge of S/4 HANA.
  • People-management experience, including developing, mentoring, and coaching.
  • Experience working in a global or regional setting.
  • Experience in a large-scale business transformation program.
  • Experience managing a product backlog or release plan, tracking team-level metrics, attending product-team ceremonies, and removing blockers.
  • Focus on business agility, Agile delivery with a fail-fast mindset, and measurable outcomes.
  • Contributes ideas that challenge existing thinking.
  • A constant learner who looks for new ways to implement features and functions that improve customer satisfaction.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.